Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.

No sooner did Eli Lilly (NYSE: LLY)’s oral diabetes candidate orforglipron make history Thursday as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to ace a Phase ...

Learn More » Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly (NYSE: LLY). But now, an investment in Lilly may not look so enticing as the possibility of ...

Daniel Krug was arrested at a King Soopers store on Dec. 16, 2023. His wife, Kristil Krug, was found dead inside the garage of their home on Promontory Lane shortly before 1 p.m. on Dec. 14.

"Be mindful about what you're sharing, because once it's online, it's online forever," says Lilly Sabri. The fitness influencer, who has six million followers on YouTube, has urged fans to heed ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant ...

Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, sending shares in the US drugmaker up nearly 15 per cent in Wall Street ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...

Lilly should be the market leader in diabetes and obesity within the next five years. The company is also poised to be a major player in several other indications. Lilly's prospects of becoming ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...